
|Videos|June 24, 2015
Afatinib Versus Erlotinib in Advanced SCC of the Lung
Author(s)Shirish Gadgeel, MD
Shirish Gadgeel, MD, Barbara Ann Karmanos Cancer Institute, discusses a phase III study examining afatinib versus erlotinib as a second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement



















